Rodman & Renshaw Terminates China Cord Blood Coverage

Rodman & Renshaw terminates its China Cord Blood

coverage in a research report published today. Rodman & Renshaw's last rating for China Cord Blood was a Market Outperform / Speculative Risk rating and a $6 price target. In the report, Rodman & Renshaw states, "Effective immediately, we are terminating coverage of China Cord Blood Corp (CCBC) to better distribute resources throughout our coverage universe." Shares of China Cord Blood closed today at $3.55, up 1.45% from Thursday's market close.